DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Pharmacokinetic and Pharmacodynamic Interactions Between the Cholesterol-lowering Ezetimibe and the Non-nucleoside Reverse Transcriptase Inhibitor Efavirenz During Chronic Treatment in Healthy Volunteers With Reference to Intestinal Expression of CYP3A4, UGT1A1, ABCB1 and ABCC2

Information source: University Medicine Greifswald
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Pharmacokinetics; Drug Interactions; Pharmacodynamics; Intestinal Transporter Expression

Intervention: Ezetrol (ezetimibe) multiple dose (Drug); Ezetrol (ezetimibe) multiple dose and Sustiva (efavirenz) single dose (Drug); Ezetrol (ezetimibe) and Sustiva (efavirenz) multiple dose (Drug); Sustiva (efavirenz) single dose (Drug)

Phase: Phase 1

Status: Completed

Sponsored by: University Medicine Greifswald

Official(s) and/or principal investigator(s):
Werner Siegmund, Prof, Principal Investigator, Affiliation: Department of Clinical Pharmacology

Summary

The purpose of this study is to evaluate the effects of a chronic co-medication of efavirenz on pharmacokinetics and sterol-lowering effects of ezetimibe at steady-state in healthy subjects genotyped for ABCB1, ABCC2, CYP2B6 and UGT1A1.

Clinical Details

Study design: Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science

Primary outcome:

AUC0-24h of Free Ezetimibe (Steady-state Pharmacokinetic After Chronic Treatment With 10 mg Ezetimibe) on Study Day 15

AUC0-24h of Free Ezetimibe (Steady-state Pharmacokinetic After Chronic Treatment With 10 mg Ezetimibe and Concomitant Single Dose Administration of 400 mg Efavirenz) on Study Day 16

AUC0-24h of Free Ezetimibe (Steady-state Pharmacokinetic After Chronic Treatment With 10 mg Ezetimibe and Concomitant Chronic Treatment With 400 mg Efavirenz) on Study Day 30

Cmax of Free Ezetimibe (Steady-state Pharmacokinetic After Chronic Treatment With 10 mg Ezetimibe) on Study Day 15

Cmax of Free Ezetimibe (Steady-state Pharmacokinetic After Chronic Treatment With 10 mg Ezetimibe and Concomitant Single Dose Administration of 400 mg Efavirenz) on Study Day 16

Cmax of Free Ezetimibe (Steady-state Pharmacokinetic After Chronic Treatment With 10 mg Ezetimibe and Concomitant Chronic Treatment With 400 mg Efavirenz) on Study Day 30

AUC of Efavirenz (Single Dose Pharmacokinetic After Treatment With 400 mg Efavirenz) on Study Days 1-5

AUC of Efavirenz (Single Dose Pharmacokinetic After Treatment With 400 mg Efavirenz and Concomitant Chronic Treatment of 10 mg Ezetimibe) on Study Days 16-20

AUC0-24h of Efavirenz (Steady State Pharmacokinetic After Chronic Treatment With 400 mg Efavirenz and Concomitant Chronic Treatment of 10 mg Ezetimibe) on Study Day 30

Cmax of Efavirenz (Single Dose Pharmacokinetic After Treatment With 400 mg Efavirenz) on Study Days 1-5

Cmax of Efavirenz (Single Dose Pharmacokinetic After Treatment With 400 mg Efavirenz and Concomitant Chronic Treatment of 10 mg Ezetimibe) on Study Days 16-20

Cmax of Efavirenz (Steady State Pharmacokinetic After Chronic Treatment With 400 mg Efavirenz and Concomitant Chronic Treatment of 10 mg Ezetimibe) on Study Day 30

Secondary outcome:

AUC0-24h of Ezetimibe Glucuronide (Steady-state Pharmacokinetic After Chronic Treatment With 10 mg Ezetimibe) on Study Day 15

AUC0-24h of Ezetimibe Glucuronide (Steady-state Pharmacokinetic After Chronic Treatment With 10 mg Ezetimibe and Concomitant Single Dose Administration of 400 mg Efavirenz) on Study Day 16

AUC0-24h of Ezetimibe Glucuronide (Steady-state Pharmacokinetic After Chronic Treatment With 10 mg Ezetimibe and Concomitant Chronic Treatment With 400 mg Efavirenz) on Study Day 30

Cmax of Ezetimibe Glucuronide (Steady-state Pharmacokinetic After Chronic Treatment With 10 mg Ezetimibe) on Study Day 15

Cmax of Ezetimibe Glucuronide (Steady-state Pharmacokinetic After Chronic Treatment With 10 mg Ezetimibe and Concomitant Single Dose Administration of 400 mg Efavirenz) on Study Day 16

Cmax of Ezetimibe Glucuronide (Steady-state Pharmacokinetic After Chronic Treatment With 10 mg Ezetimibe and Concomitant Chronic Treatment With 400 mg Efavirenz) on Study Day 30

Eligibility

Minimum age: 18 Years. Maximum age: 45 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- age: 18 - 45 years

- sex: male and female

- ethnic origin: Caucasian

- body weight: 19 to 27 kg/m²

- good health as evidenced by the results of the clinical examination, ECG, and the

laboratory check-up, which are judged by the clinical investigator not to differ in a clinical relevant way from the normal state

- written informed consent

Exclusion Criteria:

- existing cardiac or haematological diseases and/or pathological findings, which might

interfere with the drug's safety, tolerability, absorption and/or pharmacokinetics

- existing hepatic and renal diseases and/or pathological findings, which might

interfere with the drug's safety, tolerability, absorption and/or pharmacokinetics

- existing gastrointestinal diseases and/or pathological findings, which might

interfere with the drug's safety, tolerability, absorption and/or pharmacokinetics

- acute or chronic diseases which could affect drug absorption or metabolism

- history of any serious psychological disorder

- drug or alcohol dependence

- positive drug or alcohol screening

- smokers of 10 or more cigarettes per day

- positive anti-HIV-test, HBs-Ag-test or anti-HCV-test

- volunteers who are on a diet which could affect the pharmacokinetics of the drug

- heavy tea or coffee drinkers (more than 1L per day)

- lactation and pregnancy test positive or not performed

- volunteers suspected or known not to follow instructions

- volunteers who are unable to understand the written and verbal instructions, in

particular regarding the risks and inconveniences they will be exposed to as a result of their participation in the study

- volunteers liable to orthostatic dysregulation, fainting, or blackouts

- blood donation or other blood loss of more than 400 ml within the last 12 weeks prior

to the start of the study

- participation in a clinical trial during the last 3 months prior to the start of the

study

- less than 14 days after last acute disease

- any systemically available medication within 4 weeks prior to the intended first

administration unless because of the terminal elimination half-life complete elimination from the body can be assumed for the drug and/or its primary metabolites (except oral contraceptives)

- repeated use of drugs during the last 4 weeks prior to the intended first

administration, which can influence hepatic biotransformation (e. g. barbiturates, cimetidine, phenytoin, rifampicin)

- repeated use of drugs during the last 2 weeks prior to the intended first

administration which affect absorption (e. g. laxatives, metoclopramide, loperamide, antacids, H2-receptor antagonists)

- intake of grapefruit containing food or beverages within 7 days prior to

administration

- known allergic reactions to the active ingredients used or to constituents of the

pharmaceutical preparation

- subjects with severe allergies or multiple drug allergies

Locations and Contacts

Department of Clinical Pharmacology, Greifswald 17489, Germany
Additional Information

Starting date: March 2009
Last updated: September 23, 2010

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017